Prognostic Value Of The Marker P63 In Adenocarcinoma Of Lung, Breast, And Pancreas

Study Overview

Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing apoptosis. Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma. In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients' medical records as well as assessing the histological sections and performing immunohistochemical staining for p63.

N/A

Lung Adenocarcinoma
Breast Adenocarcinoma
Pancreatic Ductal Adenocarcinoma

OTHER: their will be no intervention in any of the groups, the study is retrospective

0298-13ctil

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2013-08-22	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2013-09-10
First Submitted that Met QC Criteria 2013-09-10	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2013-09-16
First Posted (ESTIMATED) 2013-09-16	Results First Posted N/A	Last Verified 2013-09

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: Lung adenocarcinoma This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.	OTHER: their will be no intervention in any of the groups, the study is retrospective
: Breast adenocarcinoma This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.	OTHER: their will be no intervention in any of the groups, the study is retrospective
: Pancreatic ductal adenocarcinoma This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.	OTHER: their will be no intervention in any of the groups, the study is retrospective

Participant Group/Arm

Intervention/Treatment

: Lung adenocarcinoma

This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

OTHER: their will be no intervention in any of the groups, the study is retrospective

: Breast adenocarcinoma

This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

OTHER: their will be no intervention in any of the groups, the study is retrospective

: Pancreatic ductal adenocarcinoma

This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

OTHER: their will be no intervention in any of the groups, the study is retrospective

Primary Outcome Measures	Measure Description	Time Frame
5 year overall survival	if the patient is alive or dead 5 years following the treatment	5 years

Secondary Outcome Measures	Measure Description	Time Frame
recurrence free survival	the recurrence of the disease within 5 years from the treatment	5 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Patients who were treated at our institution for lung adenocarcinoma, breast adenocarcinoma, or pancreatic ductal adenocarcinoma.
Available histopathological diagnosis of the malignancy.

Patients with inoperable tumors.
Patients with second primary tumor.
Patients with pathological blocks not enough for future slicing.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record